Keep pulling the thread on Will Mauldin.
Rivana Medical has a pending FDA clearance for a non-ultrasound-based needle tip tracking technology for its epidural guidance platform.
Rivana Medical's mission is to innovate in clinical areas where imaging technology is not currently used by introducing imaging combined with AI models to automate decisions.
Rivana Medical has developed an AI-enabled, handheld device described as a "stud finder for the spine" to provide guidance for epidural spinal anesthesia procedures.
Rivana Medical is introducing a second-generation epidural guidance device that will track a needle's position all the way to the epidural space to improve procedure safety.
Rivana Medical is developing an automated fracture detection device.
Rivana Medical's go-to-market strategy for its epidural device is to initially position its AI interpretation as a secondary confirmation to a clinician's own reading of the ultrasound image.
Will Mauldin has observed that after 5 to 10 procedures, clinicians using Rivana Medical's epidural device begin to rely solely on the AI interpretation.
Will Mauldin observed sentiment at the January JPMorgan Healthcare Conference that strategic acquirers in medtech may start making deals at an earlier stage than the recent trend of waiting for commercial revenue.
The commercial launch of Rivana Medical's epidural guidance platform is contingent on receiving FDA clearance for its needle tip tracking technology.
Rivana Medical has trained an AI model for fracture detection using a dataset of 1,500 cases from 8 clinical sites.
Will Mauldin believes Rivana Medical's fracture detection training dataset, which matches 3D musculoskeletal data with X-rays for 1,500 cases, is one of the largest of its kind.
Rivana Medical plans to submit its AI model for fracture detection for FDA clearance in the near future.